Syndax Pharmaceuticals SNDX Total Non-Current Liabilities
Total Non-Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesNoncurrent.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's total non-current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's total non-current liabilities?
- Syndax Pharmaceuticals (SNDX) reported total non-current liabilities of $344.87M in Q1 2026.
- How has Syndax Pharmaceuticals's total non-current liabilities changed year-over-year?
- Syndax Pharmaceuticals's total non-current liabilities increased by 4.2% year-over-year, from $331.1M to $344.87M.
- What is the long-term trend for Syndax Pharmaceuticals's total non-current liabilities?
- Over 5 years (2020 to 2025), Syndax Pharmaceuticals's total non-current liabilities has grown at a 63.5% compound annual growth rate (CAGR), from $29.55M to $344.96M.
- What does total non-current liabilities mean?
- The sum of all long-term obligations due beyond one year — long-term debt, lease liabilities, pension obligations, and deferred items.